Dodecyl creatine ester therapy: from promise to reality.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
17 Apr 2024
Historique:
received: 18 01 2024
accepted: 05 03 2024
revised: 26 02 2024
medline: 19 4 2024
pubmed: 18 4 2024
entrez: 17 4 2024
Statut: epublish

Résumé

Pathogenic variants in SLC6A8, the gene which encodes creatine transporter SLC6A8, prevent creatine uptake in the brain and result in a variable degree of intellectual disability, behavioral disorders (e.g., autism spectrum disorder), epilepsy, and severe speech and language delay. There are no treatments to improve neurodevelopmental outcomes for creatine transporter deficiency (CTD). In this spotlight, we summarize recent advances in innovative molecules to treat CTD, with a focus on dodecyl creatine ester, the most promising drug candidate.

Identifiants

pubmed: 38632116
doi: 10.1007/s00018-024-05218-y
pii: 10.1007/s00018-024-05218-y
pmc: PMC11024018
doi:

Substances chimiques

Creatine MU72812GK0
Plasma Membrane Neurotransmitter Transport Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

186

Informations de copyright

© 2024. The Author(s).

Références

Science. 2004 Jul 2;305(5680):96-9
pubmed: 15232109
J Inherit Metab Dis. 2014 Sep;37(5):715-33
pubmed: 24789340
Clin Genet. 2011 Mar;79(3):264-72
pubmed: 20528887
Mol Genet Metab. 2023 Nov;140(3):107694
pubmed: 37708665
Neuropediatrics. 2002 Oct;33(5):232-8
pubmed: 12536364
Am J Hum Genet. 2004 Jul;75(1):97-105
pubmed: 15154114
Hum Mutat. 2015 Jan;36(1):69-78
pubmed: 25265257
JCI Insight. 2021 Sep 8;6(17):
pubmed: 34324436
Front Mol Neurosci. 2023 Mar 24;16:1118707
pubmed: 37063368
Nanomedicine (Lond). 2015 Jan;10(2):185-91
pubmed: 24559037
J Med Chem. 2013 Jun 27;56(12):5173-81
pubmed: 23697594
Regul Toxicol Pharmacol. 2020 Nov;117:104750
pubmed: 32745584
Nanomedicine (Lond). 2019 Jun;14(12):1579-1593
pubmed: 31038003
Mol Genet Metab. 2022 Jan;135(1):15-26
pubmed: 34972654
Brain Sci. 2023 Sep 28;13(10):
pubmed: 37891751
Hippocampus. 2012 Feb;22(2):309-19
pubmed: 21080410
Metab Brain Dis. 2018 Jun;33(3):875-884
pubmed: 29435807

Auteurs

Aloïse Mabondzo (A)

Paris Saclay University, CEA, Medicines and Healthcare Technologies Department (MTS), SPI, Neurovascular Unit Research and Therapeutic Innovation Laboratory, 91191, Gif-sur-Yvette cedex, France. Aloise.mabondzo@cea.fr.

Jiddeke van de Kamp (J)

Department of Human Genetics, Amsterdam UMC, Vrije Universtiteit Amsterdam, Amsterdam, The Netherlands.

Saadet Mercimek-Andrews (S)

Department of Medical Genetics, Faculty of Medicine and Dentistry, Neurosciences and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH